Enyedy punts | IMGN Message Board Posts

ImmunoGen, Inc.

  IMGN website

IMGN   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  50277 of 50376  at  1/16/2020 2:15:50 PM  by

Bibliobiftek

The following message was updated on 1/16/2020 2:22:43 PM.

 In response to msg 50276 by  WilCravenMckrye
view thread

Re: Enyedy punts

The sheer number of trials they need to run makes SORAYA a must succeed event from a cash runway point of view. They will probably be down to their last $50mm post SORAYA, and it wouldn't be a bad idea to top off and structure a partnership with a contingency for possible SORAYA failure or regulatory over-caution regarding the result. It also wouldn't be a bad idea to have a partner to co-develop MS and 632 combos and bring in timewise some potential cash flows.  


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 1     Views: 303
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
50278 Re: Enyedy punts WilCravenMckrye 0 1/16/2020 4:21:44 PM






About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...